Tardive Dyskinesia Update

Steve Stoner, PharmD, BCPP

Chair and Clinical Professor
Division of Pharmacy Practice and Administration
University of Missouri - Kansas City School of Pharmacy

Learning Objectives

Review 2020 American Psychiatric Association Guidelines for the treatment of patients with schizophrenia who develop tardive dyskinesia.
Critique short and long-term treatment considerations for managing tardive dyskinesia and discuss the role of VMAT2 inhibitors in the treatment continuum of tardive dyskinesia
Explore the detrimental impact of tardive dyskinesia on global functionality and demonstrate how VMAT2 inhibitors can improve functionality and overall quality of life (e.g., improved mobility, self- care, social activities, and life responsibilities).

Activity Description

This program consists of 1 video and downloadable resources in PDF format. To begin, take the ungraded pre-test for the module below. Review the video and handout(s), then complete the post-test ( > 70% within 5 attempts) and evaluation. CPE credit will automatically upload to CPE Monitor (allow 7 days).

Continuing Education Credit

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for 0.150 CEUs (1.50 contact hour) of continuing education credit. In order to receive 1.50 contact hour of CE credit, the participant must complete the online pre-test (ungraded), watch the included video in its entirety, pass the online post-test ( > 70% within 5 attempts), and complete the online evaluation. Upon successful completion of the course evaluation, continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 7 days).

Please make sure NABP profile ID and date of birth (month/year) are entered correctly under learner's profile in this system.

Fee

$15.00

CE Hours

1.50

CE Units

0.150

Activity Type

Knowledge

Tardive Dyskinesia Update

About the Faculty

Steve Stoner, PharmD, BCPP
Chair and Clinical Professor
Division of Pharmacy Practice and Administration
University of Missouri - Kansas City School of Pharmacy

Dr. Steve Stoner is a 1994 graduate of the University of Nebraska College of Pharmacy who also completed a Psychiatric Pharmacy Residency and Fellowship at Western Missouri Mental Health Center (1994-1996). In 1996, Dr. Stoner joined the UMKC School of Pharmacy as a Clinical Assistant Professor and established a clinical practice at the Northwest Missouri Psychiatric Rehabilitation Center where he also started a Psychiatric Pharmacy Residency Program. In 2002, Dr. Stoner was promoted to Clinical Associate Professor and in 2007 was promoted to Clinical Professor. In 2008, he assumed the role of Interim Department Chair of Pharmacy Practice and became the permanent chair in 2008, a position he held until 2020. In 2020, Dr. Stoner was named the Associate Dean for Student Affairs. Dr. Stoner has held several leadership positions within local, regional, and national pharmacy organizations. Notably, Dr. Stoner is a Past-President of the College of Psychiatric and Neurologic Pharmacists Association and within the American Association of Colleges of Pharmacy he has served as the Chair of the Pharmacy Practice Section and Chair of the Council of Sections. Dr. Stoner’s scholarly endeavors have included research efforts in the disease state areas of schizophrenia, depression, drug-induced movements, and bipolar disorder. In addition, he has published in pharmacy education on topics related to course design, student learning outcomes, and student wellness as it relates to the use of smartphone devices. Dr. Stoner has also received several teaching and preceptor awards during his time at UMKC.

Disclosure: Dr. Stoner has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

• Research Grant Support: Alkermes Pharmaceuticals

• Consultant: Neurocrine Pharmaceuticals

• Speaker’s Bureau: Neurocrine Pharmaceuticals

• Honorarium: TEVA Pharmaceuticals

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

Activity Number

0067-0000-21-203-H04-P

Release Date: Oct 21, 2021

Credit Expiration Date: Oct 20, 2024

CE Hours

1.50